Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitors

Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitors

Immunotherapy for metastasized non‐small‐cell lung cancer (NSCLC) can show long‐lasting clinical responses. Selection of patients based on programmed death‐ligand 1 (PD‐L1) expression shows limited predictive value for durable clinical benefit (DCB). We investigated whether early treatment effects a...

Full description

Bibliographic Details
Main Authors: Paul van derLeest, Birgitta Hiddinga, Anneke Miedema, Maria L. Aguirre Azpurua, Naomi Rifaela, Arja terElst, Wim Timens, Harry J. M. Groen, Léon C. vanKempen, T. Jeroen N. Hiltermann, Ed Schuuring
Format: Article
Language:English
Published: Wiley 2021-11-01
Series:Molecular Oncology
Subjects:
ctDNA
droplet digital PCR
ICI treatment response monitoring
NSCLC
PD‐L1
Online Access:https://doi.org/10.1002/1878-0261.13090

Internet

https://doi.org/10.1002/1878-0261.13090

Similar Items